(Q36539008)

14 August 2017

1 reference

title

Treatment-resistant anxiety disorders (English)

1 reference

14 August 2017

Bystritsky A

1

1 reference

PubMed ID

16847460

14 August 2017

language of work or name

English

0 references

publication date

18 July 2006

1 reference

14 August 2017

1 reference

14 August 2017

11

1 reference

14 August 2017

805-814

1 reference

14 August 2017

9

1 reference

https://scigraph.springernature.com/pub.10.1038/sj.mp.4001852

14 August 2017

0 references

cites work

Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001852

Prevalence and treatment of mental disorders, 1990 to 2003

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001852

Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001852

Epidemiology, patterns of comorbidity, and associated disabilities of social phobia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001852

Subthreshold psychiatric symptoms in a primary care group practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001852

Prevalence and 12-month outcome of threshold and subthreshold mental disorders in primary care.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001852

Quality-of-life changes among patients with obsessive-compulsive disorder in a partial hospitalization program

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001852

Advances in the psychosocial treatment of anxiety disorders. Implications for national health care

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001852

World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Pharmacological Treatment of Anxiety, Obsessive-Compulsive and Posttraumatic Stress Disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001852

Cognitive-behavioral therapy, imipramine, or their combination for panic disorder: A randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001852

Neuroanatomical hypothesis of panic disorder, revised

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001852

The emotional brain, fear, and the amygdala

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001852

Neuroimaging and neurocircuitry models pertaining to the neurosurgical treatment of psychiatric disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001852

Predictors of treatment response in patients with posttraumatic stress disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001852

Predictors and outcomes in people told that they have panic attacks

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001852

A randomized effectiveness trial of collaborative care for patients with panic disorder in primary care.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001852

Perceived unmet need for mental health treatment and barriers to care among patients with panic disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001852

Treating panic disorder in primary care: a collaborative care intervention.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001852

Motivation for therapy and the results of inpatient treatment of patients with a generalized anxiety disorder: a prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001852

Does the addition of cognitive behavioral therapy improve panic disorder treatment outcome relative to medication alone in the primary-care setting?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001852

Treatment of depressive and obsessive-compulsive symptoms in OCD by imipramine and behaviour therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001852

Multivariate meta-analysis of controlled drug studies for obsessive-compulsive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001852

Use of herbal medicine in primary care patients with mood and anxiety disorders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001852

The evidence-based pharmacological treatment of social anxiety disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001852

Pregabalin: a new anxiolytic

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001852

Possible role of neuropeptides in obsessive compulsive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001852

Double-blind treatment with oral morphine in treatment-resistant obsessive-compulsive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001852

Social functioning and quality of life comparisons between obsessive-compulsive and schizophrenic disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001852

Emotion-focused psychotherapy for patients with panic disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001852

An update on obsessive-compulsive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001852

Acute and long-term effects of subthalamic nucleus stimulation in Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001852

Electrical stimulation of the anterior limbs of the internal capsules in patients with severe obsessive-compulsive disorder: anecdotal reports.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001852

Deep brain stimulation for refractory obsessive-compulsive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001852

Long-term treatment with vagus nerve stimulation in patients with refractory epilepsy. The Vagus Nerve Stimulation Study Group E01-E05.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001852

Vagus nerve stimulation for treatment-resistant depression: a randomized, controlled acute phase trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001852

Vagal nerve stimulation: a review of its applications and potential mechanisms that mediate its clinical effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001852

Altered cortical excitability in obsessive-compulsive disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001852

Right prefrontal repetitive transcranial magnetic stimulation in obsessive-compulsive disorder: a double-blind, placebo-controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001852

Repetitive transcranial magnetic stimulation (rTMS) in the treatment of obsessive-compulsive disorder (OCD) and Tourette's syndrome (TS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001852

Neurosurgery for intractable obsessive-compulsive disorder and depression: critical issues

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001852

21 January 2018

Stereotactic cingulotomy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001852

Quality of Life in Anxiety Disorders: A Comparison of Obsessive-Compulsive Disorder, Social Anxiety Disorder, and Panic Disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001852

How psychiatrists can build new therapies for impotence

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001852

7 January 2021

Pharmacotherapy of panic disorder: proposed guidelines for the family physician.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001852

7 January 2021

Discontinuation of benzodiazepine treatment: efficacy of cognitive- behavioral therapy for patients with panic disorder

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001852

7 January 2021

Determinants of pharmacologic treatment failure in panic disorder.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001852

7 January 2021

Remission, Residual Symptoms, and Nonresponse in the Usual Treatment of Major Depression in Managed Clinical Practice

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001852

7 January 2021

Cognitive-behavioral therapy for social anxiety disorder: supporting evidence and future directions

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001852

7 January 2021

Response acceleration with mirtazapine augmentation of citalopram in obsessive-compulsive disorder patients without comorbid depression: a pilot study.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001852

7 January 2021

Biological therapies for obsessive-compulsive disorder.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001852

7 January 2021

A review of the usefulness of the standard EEG in psychiatry.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001852

7 January 2021

Identifiers

DOI

10.1038/SJ.MP.4001852

1 reference

14 August 2017

1 reference

PubMed ID

16847460